Antimicrobials to Be Treated as New Drugs Under NDCT Rules
The Union Health Ministry's draft notification G.S.R. 983 (E) proposes adding antimicrobials to the 'New Drug' definition under the NDCT Rules, 2019.

Why in News
On 19 November 2026 the Union Ministry of Health and Family Welfare announced a draft amendment to the New Drugs and Clinical Trials Rules, 2019, that would bring antimicrobials under the 'New Drug' definition and so under central regulatory oversight.
The Union Ministry of Health and Family Welfare has put out a draft amendment that would place antimicrobials inside the legal definition of a New Drug. The change is proposed through a draft Gazette notification numbered G.S.R. 983 (E), which carries the date 6 November, and it would rewrite Rule 2(1)(w)(v) of the New Drugs and Clinical Trials Rules, 2019.
Why the ministry wants the change
The ministry's worry is that licences to manufacture antimicrobial products have in some cases been issued without the scrutiny such medicines deserve. The scrutiny it names includes bioavailability and bioequivalence studies and stability studies. Where those assessments are skipped, the quality, the safety and the effectiveness of the product cannot be vouched for. Weak or substandard antimicrobials give resistant organisms room to multiply and spread, and that leaves patients exposed.
What the amendment would require
Once an antimicrobial counts as a new drug, its maker would first have to secure permission from the Central Licensing Authority (CLA). Only with that permission in hand could the firm go to the State Licensing Authority (SLA) and ask for a manufacturing licence. The two-step route hands the Centre a supervisory say it does not have at present, and the ministry expects it to raise the standard of antimicrobials reaching the market.
The resistance backdrop
Antimicrobial resistance, shortened to AMR, is treated as a worldwide public-health priority that no country can settle on its own. The release recalls that the G20 New Delhi Leaders' Declaration had also pressed for action on resistance through the One Health approach, which studies human, animal and environmental health as one connected problem.
What happens next
This is a draft and not yet a rule in force. Objections and suggestions may be sent by members of the public and by industry to the Under Secretary (Drugs) at the health ministry, by post or by email. The window is 30 days counted from the day copies of the Gazette carrying the draft rules reach the public, and the Central Government will take its final view only after that.
For an aspirant the anchors are compact: the parent rules and the year they carry, the Gazette number of the draft, the sub-clause being amended, the order of the two licensing authorities, and the expanded form of AMR.
Important Facts
| Proposal | Antimicrobials to be included in the 'New Drug' definition |
|---|---|
| Ministry | Ministry of Health and Family Welfare |
| Parent rules | New Drugs and Clinical Trials Rules, 2019 |
| Draft notification | G.S.R. 983 (E), dated 6 November 2026 |
| Rule amended | Rule 2(1)(w)(v) |
| Prior permission from | Central Licensing Authority (CLA) |
| Manufacturing licence from | State Licensing Authority (SLA) |
| Problem addressed | Antimicrobial resistance (AMR) |
| Approach cited | One Health, as urged in the G20 New Delhi Leaders' Declaration |
| Objection window | 30 days from the date Gazette copies are made available |
Exam Point of View
Remember the parent rules (New Drugs and Clinical Trials Rules, 2019), the draft Gazette number G.S.R. 983 (E), the sub-clause Rule 2(1)(w)(v), the order Central Licensing Authority then State Licensing Authority, the full form of AMR, and the One Health approach named in the G20 New Delhi Leaders' Declaration.
Practice Questions
Under the draft amendment proposed by the Union Health Ministry, antimicrobials would be included in the definition of which term?
- A.Essential Drug
- B.New Drug
- C.Bulk Drug
- D.Habit-forming Drug
Show answer
The draft amendment would insert antimicrobials into the definition of a new drug in Rule 2(1)(w)(v) of the New Drugs and Clinical Trials Rules, 2019, so that antimicrobial products are judged by the stricter framework that applies to new drugs.
Read the full explanation →Before approaching the State Licensing Authority for a manufacturing licence for an antimicrobial, a manufacturer would have to obtain permission from which body?
- A.The Drugs Technical Advisory Board
- B.The concerned State Government
- C.The Central Licensing Authority
- D.The Indian Council of Medical Research
Show answer
The proposal sets up a sequence: a manufacturer must first win permission from the Central Licensing Authority, and only then may it ask the concerned State Licensing Authority for a licence to manufacture.
Read the full explanation →Which approach to tackling antimicrobial resistance was underscored by the G20 New Delhi Leaders' Declaration, as recalled in the proposal?
- A.The One Health approach
- B.The Zero Hunger approach
- C.The Universal Health Coverage approach
- D.The Health For All approach
Show answer
The ministry's release notes that the G20 New Delhi Leaders' Declaration stressed the need to confront antimicrobial resistance through One Health, which treats the health of people, animals and the environment as a single, linked subject rather than as separate concerns.
Read the full explanation →Frequently Asked Questions
Which rules are being amended to cover antimicrobials?
The New Drugs and Clinical Trials Rules, 2019. Draft notification G.S.R. 983 (E) would add antimicrobials to the definition of 'New Drug' in Rule 2(1)(w)(v) of those rules.
Whose permission will antimicrobial manufacturers need first?
The Central Licensing Authority's. Only after that permission is granted may a manufacturer apply to the State Licensing Authority for a manufacturing licence, which gives the Centre a supervisory role it lacks today.
What does AMR mean and why does it matter here?
AMR is antimicrobial resistance. Substandard or ineffective antimicrobials help resistance build up and travel, so the ministry wants quality, safety and efficacy examined centrally before manufacture is allowed.
Sources
- https://www.pib.gov.in/PressReleasePage.aspx?PRID=2338243 (opens in a new tab) — Press Information Bureau
Current Affairs 19 November 2026
- Separate Wholesale Licence Proposed for Bulk Drugs in IndiaNational
- SVANidhi Samman Awards 2026 to Honour Street Vendor WorkGovernment Schemes
- CSIR Transfers Bio-Bitumen and UHPC Road Technologies to IndustryScience & Technology
- CMOT Brings 100 Young Film Talents to 57th IFFI in GoaNational
- CSIR-TKDL and IKS Division Sign MoU on Traditional KnowledgeNational
- BHASHINI Shows Voice-First Language AI at Dakshin Day 2026Science & Technology
- IAF Signs MoU With Central Sanskrit University for Yoga CoursesDefence
- PM Modi Opens FICCI Centenary Convention at Bharat MandapamEconomy
Related Current Affairs
- National
Gadkari Addresses 85th Indian Roads Congress Session at Hyderabad
19 November 2026 · 2 min read
Related GK
- Famous Personalities of Rajasthan: Exam Notes
28 October 2026 · Rajasthan
- Districts and Divisions of Rajasthan: Exam Notes
28 October 2026 · Rajasthan
- Tourism and World Heritage Sites of Rajasthan Notes
27 October 2026 · Rajasthan
Take the Quiz
- Current Affairs Quiz
State Exams Current Affairs Quiz: 19 November 2026
25 questions25 minutesStart Quiz





